Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (vol 13, 152, 2023)

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPMARTIN, ThomasDIMOPOULOS, Meletios-AthanasiosMIKHAEL, JosephYONG, KweeCAPRA, MarceloFACON, ThierryHAJEK, RomanSPICKA, IvanBAKER, RossKIM, KihyunMARTINEZ, GraciaMIN, Chang-KiPOUR, LudekLELEU, XavierORIOL, AlbertKOH, YoungilSUZUKI, KenshiCASCA, FranceMACE, SandrineRISSE, Marie-LaureMOREAU, Philippe2024-04-052024-04-052023BLOOD CANCER JOURNAL, v.13, n.1, article ID 152, 1p, 20232044-5385https://observatorio.fm.usp.br/handle/OPI/59204engopenAccessIsatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (vol 13, 152, 2023)articleCopyright SPRINGERNATURE10.1038/s41408-023-00923-6OncologyHematology